Qualigen Announced An Agreement With Marizyme To Commercialize DuraGraft

(RTTNews) - Tuesday, Qualigen Therapeutics, Inc. (QLGN) announced a co-development agreement with Marizyme, Inc. to advance the commercialization of Marizyme's product, DuraGraft.

DuraGraft, which received De Novo FDA Clearance on October 4, 2023, is designated for use as a vascular conduit solution for adult patients undergoing Coronary Artery Bypass Grafting surgeries.

As per the Agreement, Qualigen will assist in launching DuraGraft in the United States and fund post-clearance clinical studies to promote its usage in the U.S., by providing up to $1.5 million in funding over the next several months for these initiatives.

In exchange, Qualigen will earn a portion of Marizyme's gross profit from future U.S. product sales, limited to a 2X return on their invested capital.

Furthermore, Qualigen has secured an exclusive negotiation period until May 31, 2024, to suggest and outline a broader strategic relationship between the two companies.

The views and opinions expressed herein are the views and opinions of the author and do not necessarily reflect those of Nasdaq, Inc.


More Related Articles

Info icon

This data feed is not available at this time.

Sign up for the TradeTalks newsletter to receive your weekly dose of trading news, trends and education. Delivered Wednesdays.